Search Results for: THERAPEUTIC FOCUS A New Patented
Articles
MorphoSys & Immatics Biotechnologies Enter Strategic Alliance August 31, 2015
MorphoSys AG and Immatics Biotechnologies GmbH recently announced a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer...Halozyme Enters Lucrative Global Collaboration & Licensing Agreement June 9, 2015
Halozyme Therapeutics, Inc. recently announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary...PlasmaTech Biopharmaceuticals Announces Major Acquisition May 12, 2015
PlasmaTech Biopharmaceuticals, Inc. recently announced it has entered into a definitive agreement to acquire Abeona Therapeutics, a company engaged in...SPECIAL FEATURE - Prefilled Syringes & Parenteral Contract Manufacturing: Anticipating the Needs of the Future May 5, 2015
Contributor Cindy H. Dubin speaks with several companies in the prefilled syringe and parenteral manufacturing market that are offering a range of services and systems that cater to today’s issues as well as anticipating the needs of the future.
THE SECOND QUADRANT - The Birth of Drug Solubilization: 1840 Through 1920 March 31, 2015
Marshall Crew, PhD, indicates that while it may seem as if today’s technologies for dealing with solubilization challenges have emerged throughout the past 2 decades, their maturation took over a century, and this process itself is an interesting study in innovation diffusion.
SPECIAL FEATURE - Bioavailability & Solubility: A Demand for Enhanced Technologies & Materials is Spurring Innovation March 3, 2015
Contributor Cindy H. Dubin spoke with several contract research/manufacturing organizations on how they are successfully overcoming solubility/bioavailability challenges, such as matching APIs to formulations and choosing the best excipients.
Sanofi & MannKind Announce Afrezza, the Only Inhaled Insulin, Now Available in the US February 4, 2015
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by...SPECIAL FEATURE - Injectable Drug Delivery: Safer, Simpler, Smarter Devices September 4, 2014
Contributor Cindy H. Dubin speaks with some of the leading companies operating in the injectables arena, and discovers this ever-evolving sector is witnessing some very specific and eye-opening trends that are affecting the market’s growth.
SPECIAL FEATURE - Patients & Physicians Desire Transdermal, Topical & Subcutaneous Delivery July 9, 2014
Contributor Cindy H. Dubin recently interviewed several topical, transdermal, and subcutaneous product manufacturers to find out how they are working with patients and physicians to develop delivery systems that meet their needs for comfort, compliance, and more effective delivery.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Early-Stage Partnerships Are On The Rise April 2, 2014
Contributor Cindy H. Dubin asked leading CMOs and CDMOs to describe the value-added services they offer with respect to formulation and manufacturing. Solving challenges of insufficient solubility, poor stability, identifying excipient candidates, and particle design topped their list of offerings.
CELL THERAPIES - The Challenges & Possible Solutions for Transferring Cell Therapy From the Bench to the Industry March 6, 2014
Lior Raviv, MMedSc, and Ohad Karnieli, PhD, discuss the significant emerging challenges in downstream processing of cell therapies focused mostly on allogeneic therapies.
EXECUTIVE INTERVIEW - Hermes Pharma: User-Friendly Dosage Forms, a Win-Win Situation for Patients & Pharma March 5, 2014
Drug Development Executive: Dr. Thomas Hein, Director, Sales & Business Development at Hermes Pharma, discusses how user-friendly dosage forms help put patients first, their advantages for patients and pharmaceutical companies, as well as the challenges associated with their development and production.
MARKET BRIEF - Latin America Next-Generation Biosimilars Market: Opportunities & Future Growth March 4, 2014
Lucila Rocca, Healthcare Industry Analyst, Frost & Sullivan, indicates the Latin American Biosimilars market will grow at a significant rate in the next 5 years, and the importance of establishing rigorous regulation will stimulate this market growth.
ROUNDTABLE DISCUSSION: Reformulating Opioids to Deter Abuse January 8, 2014
Contributor Cindy H. Dubin talks with some leading Specialty Pharma companies to find out how they are formulating technologies to deter the growing problem of opioid abuse.
BioDelivery Sciences International Announces NDA Acceptance October 14, 2013
BioDelivery Sciences International, Inc. recently announced that its NDA for BUNAVAIL (buprenorphine naloxone buccal film) for the maintenance treatment of...SPECIAL FEATURE - Transdermal, Topical & Subcutaneous Drug Delivery: Extending Pipelines & Improving Self-Administration July 20, 2013
Contributor Cindy H. Dubin explores how the movement of home care and self- administration is pushing the development of this growing sector in drug delivery.
FORMULATION DEVELOPMENT - Trends & Opportunities in Particle Design Technologies - Life Sciences & Biopharma in the Spotlight April 30, 2013
Frost & Sullivan Analyst, Cecilia Van Cauwenberghe, MS, examines the observed trends in particle design and engineering technologies, as well as the main factors and opportunities driving the principal technological advances in the biopharmaceutical industry.
INNOVATION AWARDS - Drug Delivery Award Winners Move Innovation Needle; Formulation Takes Center Stage March 31, 2013
Marc Dresner presents the three companies that were honored by their industry peers with prestigious awards for breakthrough drug delivery innovation at the Institute for International Research’s 17th annual Drug Delivery Partnerships conference.
1/23/2012 January 21, 2013
Amgen Invests $200 Million in Monoclonal Antibodies Amgen recently announced plans to build a new manufacturing facility in the Tuas...1/9/2013 January 3, 2013
Ultragenyx Secures $75 Million for Ultra-Rare Diseases Ultragenyx Pharmaceutical Inc. recently announced the successful completion of a $75-million Series B...
